The long-awaited shift in federal cannabis policy has finally arrived, at least in part. In April, the U.S. Department of Justice formally reclassified state-licensed medical marijuana from Schedule I to Schedule III. The historic move acknowledges the plant’s accepted medical use and significantly reduces the regulatory barriers that have defined the industry for decades.
For operators, the immediate implications are meaningful. The change allows cannabis businesses operating within state-licensed medical frameworks to claim federal tax deductions previously disallowed under Internal Revenue Code Section 280E. It also easing restrictions on research and bringing federal policy closer in line with the realities of a market that already exists across most of the country. It is, by any measure, a significant step forward.
That said, rescheduling is not a solution to the cannabis industry’s current exit problem.
Why rescheduling won’t solve the cannabis liquidity crisis
Rescheduling has been framed, in many circles, as the catalyst that will unlock capital, restore compressed valuations, and bring institutional buyers back into the market. However, that expectation misunderstands both the scope of the change and the structure of the industry itself.
The current reclassification applies narrowly to state-licensed medical cannabis and FDA-approved products. Consider the limitations:
- No federal legalization: It does not legalize marijuana federally.
- Persistent fragmentation: It does not resolve the regulatory fragmentation between state and federal systems.
- No influx of buyers: It does not suddenly create a pool of well-capitalized acquirers ready to deploy meaningful capital into the space.
The market’s reaction already has made that clear. Publicly traded cannabis companies’ shares initially rallied on the rescheduling announcement, only to pull back as investors recalibrated expectations around what the policy actually changes.
The reality of a capital-constrained market
The underlying reality remains intact. Cash buyers are still scarce. Transactions continue to rely on seller financing, equity swaps, and hybrid corporate structures. Distressed assets continue moving at compressed valuations, and operators are still consolidating in order to survive instead of scaling aggressively.
These are not temporary distortions waiting to be corrected by policy. They are structural characteristics of a capital-constrained market.
At the same time, the industry is entering a period where policy signals are becoming more complex, not less. The administration already has indicated broader rescheduling efforts will move through hearings beginning this summer, introducing further uncertainty about timing, scope, and implementation. Meanwhile, operators are preparing for additional regulatory inflection points, including the anticipated changes to hemp-derived products in late 2026, which could reshape revenue streams across multiple categories.
Taken together, these dynamics point to a shift that is easy to overlook. Cannabis is moving away from a period defined by binary policy outcomes and toward one defined by ongoing regulatory evolution. In this environment, waiting for a single external event to unlock liquidity is not a viable strategy. Structure is.
Structural solutions: the benefits of an independent buyout
Behind every successful business outcome is a structure — designed, deliberate, and built to last.
One transaction framework directly addresses the pressures operators continue to face, yet it remains widely misunderstood. Most recognize it by the acronym ESOP, or employee stock ownership plan, which often leads to it being dismissed before it is properly evaluated. In practice, what is emerging more frequently in the cannabis sector is better understood as an independent buyout.
How an independent buyout works
Under an ESOP independent buyout model:
- A federally authorized trust purchases shares directly from the founder.
- The transaction is often funded using third-party debt.
- The founder receives liquidity, may defer capital gains taxes, and can continue operating the business.
Through this method, ownership transitions, but control and continuity do not disappear.
The tax advantage for cannabis operators
On its own, that presents a viable alternative in a market where traditional buyers remain limited. In the context of cannabis, the implications are more significant. A company that is 100-percent owned by an ESOP trust operates without federal and state income tax. That structural shift fundamentally alters the economics of the business, allowing cash that otherwise would leave the company to be redeployed into:
- Rapid debt reduction.
- Capital reinvestment.
- Operational strengthening.
This matters more now than it did a year ago. Rescheduling may reduce tax pressure by alleviating Section 280E for certain medical-cannabis operators, but it does so unevenly and within an incomplete framework. An independent buyout does not depend on the sluggish pace or narrow scope of federal reform. It creates a structure where tax efficiency is embedded into the business itself, rather than contingent on policy outcomes that may continue to evolve.
That distinction is becoming increasingly important. The industry already is consolidating. Operators are combining assets, absorbing distressed businesses, and searching for ways to build scale without relying on capital that has yet to return. Within that environment, structure becomes more than a transaction mechanism. It becomes a way to compound cash flow, improve resilience, and create growth that is internally funded rather than externally dependent.
Overcoming barriers to ESOP adoption in cannabis
This structural distinction is becoming increasingly important as the industry consolidates. Operators are currently combining assets, absorbing distressed businesses, and searching for ways to build scale without relying on institutional capital that has yet to return. Within this environment, corporate structure becomes more than a transaction mechanism; it becomes a way to compound cash flow, improve resilience, and create growth that is internally funded rather than externally dependent.
Despite these advantages, the primary barrier to adoption is not economic. It is conceptual. Many operators never fully evaluate this approach because the term “ESOP” carries assumptions that do not reflect how the structure is being leveraged in modern corporate finance. In a volatile market, that kind of misalignment can be costly.
Designing your own exit outcome
Rescheduling undeniably represents progress. It validates years of industry advocacy and signals a meaningful change in how federal policymakers view cannabis. But it does not replace the need for operators to actively design their own exit outcomes.
Cannabis is entering a maturity phase where competitive advantage will be defined less by raw access to capital and more by how effectively that capital is structured. Policy and regulatory frameworks will continue to evolve, but those developments will not determine individual corporate success on their own.
An independent buyout is not a universal solution. It is, however, one of the few corporate structures that directly addresses liquidity, tax efficiency, and operational control within the constraints that still define the cannabis industry. At a time when many are looking to Washington for answers, it offers a different approach — one grounded not in what may change, but in what can be built now.
As managing partner at MBO Ventures, serial entrepreneur and prolific angel investor Darren Gleeman assists clients with employee stock ownership plans (ESOPs) and capital management. Previously, he served as managing partner at hedge fund GB Trading. Gleeman holds a patent on ESOP methodology for the cannabis industry and received Green Market Report’s 2024 Top Financial Advisor award.
